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Background: Adherence to anti-malarial dosing schedules is essential to ensure effective treatment. Measuring
adherence is challenging due to recall issues and the participants’ awareness of the desired behaviour influencing
their actions or responses. This study used qualitative methods, which allow for rapport building, to explore issues
around anti-malarial utilization in young children, and used the results to guide the development of a context
specific questionnaire on perceptions and adherence to artemether-lumefantrine (AL) and dihydroartemisinin-
piperaquine (DHA-PPQ).
Methods: Qualitative data collection included 12 focus group discussions which explored community perceptions
of anti-malarials and experiences of administering medications to children. Critical incidence interviews were
conducted with 22 caregivers to explore experiences of administering the dispersible or original formulation of AL
to young children during recent febrile episodes. A structured questionnaire was used to gather data on experience
of recent treatment and adherence to anti-malarials during follow-up visits with 218 caregivers whose child was
recently treated with either dispersible AL or DHA-PPQ.
Discussion/Conclusion: Caregivers experience great difficulty in administering medication to children. While the
sweet taste of dispersible AL may have reduced conflict between the child and caregiver, sub-optimal dosing due
to medication loss remained a problem and overall adherence was greater among those receiving DHA-PPQ,
which requires fewer doses. Some caregivers were found to deliberately alter the dosing schedule according to
whether they perceived the medication to be too weak or strong. They also developed theories for poor treatment
outcomes, such as attributing this to lack of compatibility between the medication and the child. Health education
messages should be strengthened to ensure a combination of clear pictorial and verbal instructions are used
during dispensing, and consequences of under and over-dosing are explained alongside appropriate responses to
possible adverse events. Further optimizing of anti-malarial adherence among children requires the development of
anti-malarials with pharmacological properties that allow user-friendly administration and simplified dosing schedules.
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Artemisinin-based combination therapy (ACT) is highly
efficacious [1-3], however there are many barriers to en-
suring that these drug combinations reach those that
need them and that they are used appropriately. Poor
adherence to anti-malarial treatment is associated with
worsening of symptoms and increased risk of treatment
failure and re-infection rates [4-9]. Widespread under-
dosing fuels the spread of low-grade drug resistance in a
population. Since the introduction of ACT, there has been
increasing concern about adherence to anti-malarials. The
dosing schedules of ACT is more complex than the previ-
ous first-line therapy, sulphadoxine-pyrimethamine (SP)
and should resistance to artemisinins become widespread,
there are few alternatives.
Adverse events are known to impact on adherence
[4,10-13], although ACT has been found to be well-
tolerated [1,3,14-16]. Correct understanding of the dosing
schedule is essential for adherence [4,10,12,15,17-20]. Dif-
ficulty in administering medication to children has been
reported by caregivers and shown to impact on adherence
[4,18] and caregivers have been found to dislike the re-
quired crushing of tablets for young children [21]. The
bitter taste of anti-malarials for children is a frequent
complaint [18,21] and the full course of medication may
not be administered if the child dislikes it [13,22]. Adher-
ence has been found to drop-off towards the end of the
treatment regime, even for short-term courses [4,23].
Previous experience in Malawi during the change from
chloroquine to SP highlighted the importance of asses-
sing the acceptability of any newly introduced drug [24].
Data on reported adherence must be supplemented with
an understanding of why individuals use medications the
way they do, in order to appropriately develop interven-
tions to target such issues [25,26]. The Ministry of Health
in Malawi is starting to deploy ACT through community
health workers operating from rural health posts, starting
from so-called hard-to-reach-areas: a good understanding
of factors influencing utilization in this context will assist
the effective development of such an intervention.
A study was conducted with the aim of exploring,
caregiver’s perceptions and experiences of ACT in-depth
and understanding how these influenced adherence.
Adherence to and perceptions of two different forms of
ACT were explored in young children. Two formula-
tions of artemether-lumefantrine (AL) were investigated:
the original formulation, which must be crushed for young
children, and the newer dispersible formulation which has
a sweet cherry flavour. Dihydroartemisinin-piperaquine
(DHA-PPQ) is non-dispersible and non-flavoured. In-
depth qualitative research was conducted to identify deter-
minants of adherence and inform the development of a
structured questionnaire which was then used to gather
adherence data in a larger sample.Methods
Study setting
This study was situated within Chikhwawa, a district with
high levels of poverty (82% of the population live in pov-
erty and 59% are ultra-poor) [27], situated in the southern
region. The public health system in Chikhwawa comprises
the district referral hospital, one rural hospital, one mis-
sion hospital, 14 Health Centres and 26 Community
Health Worker (CHW) operated health posts, which cater
for the district’s population of approximately 435,000 [28].
This study was nested within a community-based safety
and effectiveness trial investigating the programmatic im-
plementation of AL and DHA-PPQ (Clinical Trial ID No:
NCT010380632, http://www.actconsortium.org/projects/
18/the-actia-trial-safety-of-repeated-drug-use-in-children).
The trial enrolled children between the ages of 4 to11
months, who were randomized at village level to receive
either AL or DHA-PPQ from the health facility when mal-
aria was diagnosed, and followed up for up to three years
to assess the long term safety of ACT. Malaria in the area
of the parent trial shows high heterogeneity seasonally
and spatially with village level parasite prevalences ranging
between < 5% and > 60% within the area (D.J, Terlouw per-
sonal communication).
Study design
Data were collected using a mixture of methods. An
initial qualitative phase was conducted to explore com-
munity perceptions of anti-malarials and experiences of
administering medications to children. This involved a
series of focus group discussions (FGDs) and critical in-
cidence interviews (CIIs). Results of the qualitative phase
were then used to develop a structured questionnaire,
which gathered data on experience of recent treatment
and adherence to anti-malarials. This questionnaire was
used during follow-up (FU) visits with caregivers whose
child was participating in the parent trial, who had
attended the study-site with malaria symptoms and was
treated with either dispersible AL or DHA-PPQ.
Qualitative data collection
FGDs and CIIs were conducted between September
2010 and February 2011. Qualitative data collection was
conducted by four local fieldworkers who were trained
in qualitative research methods, with a specific focus on
conducting CIIs and FGDs and exploring issues around
anti-malarial drug use. Two female fieldworkers (one
facilitator and one note-taker) conducted FGDs with fe-
male participants and two male fieldworkers conducted
FGDs with male participants. FGD participants were se-
lected from among the community in which the parent
trial was conducted. CII participants were identified by a
continuous (‘rolling’) Malaria Indicator Survey (MIS)
which involved visits to individuals’ homes and was
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lence in the area [29].
12 FGDs and 22 CIIs were conducted in the local lan-
guage (Chichewa, although some Chisena was used in re-
mote villages) (Table 1). Six initial FGDs were conducted
followed by repeat FGDs with the same group to discuss
the earlier findings and to clarify and probe issues further.
FGDs gathered information about community knowledge
and perceptions of medicines used to treat malaria and
challenges associated with administering medications to
children. Maximum variation purposive sampling was
used to select FGD participants, ensuring that a range of
perspectives were included [30,31]. FGD participants were
selected by community advisory groups (CAGs) set up as
part of the parent trial. Each participant had one or more
children. This was not restricted by age of child, in order
to capture the views of older members of the community,
who may be important decision makers. FGDs were con-
ducted in two village clusters, representing two diverse
sub-sets of the population in the Chikhwawa district -
those living around the commercial centre of the district,
and those living in remote areas. Discussions held with
CAGs during selection emphasized the importance of
identifying ‘symbolically’ representative members of the
community; criteria included selecting individuals with
metal and straw roofs; those who lived nearer and further
from the village centre; and those from different family
groups. The team were aware of the likelihood that friends
and relatives might be selected, however previously col-
lected household wealth data suggested that within each
sub-community, individuals were fairly homogenous in
terms of possession ownership as a proxy for wealth [32].
Separate groups were conducted with younger women,
older women and men of mixed ages.
The 22 CIIs were conducted by one of the female
fieldworkers. CIIs were used to explore participants’ ex-
perience of receiving and administering anti-malarials.
The critical incident technique was first developed as a
method of observing human behaviour in order to solveTable 1 Qualitative methods
Focus group discussions1
Young women 4
Older women 4
Men 4
Total focus group discussions 12
Critical incidence interviews
Women whose child experienced fever and attended a formal
health facility
12
Women whose child experienced fever and did not attend a
formal health facility
10
Total critical incidence interviews 22
18 to 10 participants per group.practical problems, where observed events were complete
incidents with definite consequences [33]. This method
enables the participant to develop a narrative that focuses
around the particular influential event [34]. CII partici-
pants were caregivers of children under the age of five
who were identified by the MIS as having had a febrile ill-
ness during the previous two weeks. The children had ei-
ther received standard formulation AL at a health facility
(with or without an RDT-based diagnosis) or had been
treated by the survey team with dispersible AL following
a positive rapid diagnostic test. CII participants were
equally divided into those living less-than-15-minutes
and greater-than-15-minutes walk from a health centre.
Participants were asked about their experience of receiv-
ing and administering anti-malarials to their child during
the recent febrile illness. Individuals midway through a
treatment course were excluded.
Detailed topic guides were used to focus the CII and
FGDs on the areas of interest and ensure all the relevant
topics were covered [30]. However the fieldworkers were
encouraged to use the topic guide flexibly, asking ques-
tions in any order and adding questions to gain more
detail or explore topics of interest [35]. FGD Participants
were asked to discuss: which household members are
involved in administering anti-malarials to children; chal-
lenges experienced during administration; strategies for
overcoming challenges; any known negative effects of
various known anti-malarials; and how they identified and
responded to different treatment outcomes. Draft topic
guides were reviewed and refined with the fieldworkers
before and after piloting. Two small pilot FGDs were held
in villages close to the field site and pilot CIIs were held
with three caregivers who had attended the facility for
treatment. Voice recordings of pilot and all subsequent
CIIs were reviewed on return from the field; translated
transcripts of the pilot FGDs were discussed in detail,
highlighting specific areas for encouragement and train-
ing. Transcripts of each subsequent FGD were reviewed in
detail during preparation for repeat FGDs.
Quantitative data collection
Results from analysis of the qualitative data were used to
guide the development of a structured questionnaire to
explore perceptions and utilization of anti-malarials in a
larger group of participants. When participants in the
parent trial attended the clinic and were treated with
one of the two study drugs (AL or DHA-PPQ), they were
invited to participate in a FU visit that would be con-
ducted in their home. They were not made aware that this
would involve a questionnaire survey, or that they would
be questioned about their adherence. Individuals who had
participated in a CII were excluded from the survey. FU
visits were conducted by a fieldworker the day after treat-
ment should have been completed, using a structured
Table 2 Survey participant characteristics according to
whether they received Artemether-lumefantrine (AL) or
Dihydroartemisinin-piperaquine (DHA-PPQ)
Study arm
AL n(%) DHA-PPQ n(%) Pa
Child sex
Female 59 (58) 68 (58)
Male 42 (42) 49 (42) 0.97
Child age
<24 months 30 (30) 26 (22)
24-35 months 53 (52) 76 (65)
36-47 months 18 (18) 15 (13) 0.17
Maternal education
None 25 (25) 35 (30)
Primary 45 (45) 52 (44)
Secondary + 31 (31) 30 (26) 0.60
aχ2/χ2 test for trend.
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tionnaire consisted of four sections: basic demographics;
medication and any instructions received at the clinic;
the medication administration process; and drug pack-
age examination and adherence diary. Questions were
designed to demonstrate an understanding of the types
of issues experience when administering medication to
young children, in order to gain confidence and improve
accuracy of responses.
Data analysis
Qualitative analysis examined in detail issues surround-
ing anti-malarial utilization. The team met after each
qualitative data collection to review transcripts and dis-
cuss emerging themes. Qualitative data analysis was
based on a framework approach [36]. The CIIs and
FGDs were recorded, transcribed and translated into
English, then imported into the qualitative analysis soft-
ware QSR NVivo 9 for analysis. A broad index was
developed based on themes emerging from the data and
was refined throughout coding; the index was applied to
code all data. Data were charted by summarizing and
comparing data coded under different indexes and
across different categories of participants, and develop-
ing explanations.
Quantitative data analysis was conducted to establish
the proportion of children who were adherent to each
ACT. Quantitative data was analysed using Stata version
10 (Stata Corp., College Station, TX). Individuals receiv-
ing AL were considered adherent if they reported
administering tablets to their child twice daily for three
days. Those receiving DHA-PPQ were considered adher-
ent if they reported administering tablets once daily for
three days. The proportion of individuals considered ad-
herent in each group was calculated alongside odds ratios
for the relationship between adherence and drug type.
Child sex and age and maternal education were assessed
for confounding and effect modification as they may in-
fluence adherence [18,20,23,37-40]. The proportion of
caregivers who experienced challenges in administrating
ACT to children and the proportion who received and
understood instructions from the health facility were
also explored,
Ethics approval
Ethical approval was obtained from the College of Medi-
cine Research and Ethics Committee, Malawi (P.04/09/
783 and P.10/08/707) and the Liverpool School of Trop-
ical Medicine Research Ethics Committee (09.07). Per-
mission was also granted by village leaders. Sensitization
campaigns were conducted as part of the parent trial to
inform the communities about all aspects of the trial
and affiliated studies. Fully informed written consent was
obtained from all participants in the local language.Results
The results of the mixed-methods investigation is pre-
sented below. Initially quantitative data on overall adher-
ence is presented. Qualitative findings then explore factors
influencing ACT utilization, drawing on quantitative data
where relevant.Overall adherence
218 individuals participated in the survey, no one de-
clined (Table 2). Reported overall adherence was rea-
sonably good: 88% (103/117) of those who received
DHA-PPQ and 79% (80/101) of those who received AL
adhered to the dosing schedule (Crude Odds Ratio:
1.93, 95% CI 0.92-4.06, P = 0.08). There was no differ-
ence in overall adherence according to child sex. There
was a suggestion that, compared to children <24 months,
older children were more adherent overall (24-35months:
OR:1.40, 95% CI 0.63-3.09; 36-47months: 4.23, 95% CI
0.88-20.24, P = 0.07), but this did not differ between the
two study drugs. Overall, level of maternal education did
not affect adherence but there was a trend towards adher-
ence being better with DHA-PPQ than with AL in the
lower education groups (No Education: OR: 3.01, 95% CI
0.77-11.73, P = 0.10; Primary Education: OR 3.42, 95% CI
1.10-10.63, P = 0.03; Secondary Education: OR: 0.34, 95%
CI 0.06-1.94, P = 0.21) (Table 3). Only one individual, who
reported full adherence (n = 183), did not provide pack-
aging. All other individuals reporting on adherence pro-
duced empty pill packaging. One individual who received
DHA-PPQ (n = 117) and two who received AL (n = 101)
reported not completing the treatment course but had no
tablets remaining. All other participants who reported
non-adherence had tablets remaining.
Table 3 Factors influencing adherence to the ACT
Artemether-lumefantrine (LA) and Dihydroartemisinin-
piperaquine (DHA-PPQ)
Adherence to study drug
n (%) Crude odds
ratio (95% CI)
Pa
Anitmalarial
AL 80 (79) 1
DHA-PPQ 103 (88) 1.93 (0.92-4.06) 0.08
Child sex
Female 103 (81) 1
Male 80 (88) 1.69 (0.78-3.68) 0.18
Child age
<24 months 44 (79) 1
24-35 months 108 (84) 1.40 (0.63-3.09)
36-47 months 31 (94) 4.23 (0.88-20.24) 0.07
Maternal education
None 49 (82) 1
Primary 80 (83) 1.06 (0.46-2.44)
Secondary + 54 (89) 1.73 (0.62-4.82) 0.30
Adherence to AL vs DHA-PPQ Stratified by maternal education
No education 18 (72) vs 31 (89) 3.01 (0.77-11.73)
Primary education 33 (73) vs 47 (90) 3.42 (1.10-10.63)
Secondary education 29 (94) vs 25 (83) 0.35 (0.06-1.94)
Test of homogeneity: P = 0.05
aχ2/χ2 test for trend.
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The main issues that emerged from the qualitative work
were that perceptions and utilization of anti-malarials
were determined by ease of administration; perceived
strength; and understanding about the drug. Optimal ad-
herence requires ACT that is easy to administer; perceived
to be sufficiently, but not overly strong; is understood by
caregivers both in terms of appropriate dosing and pos-
sible treatment effects and outcomes. The relationship
between these factors and the influence of adverse drug
reactions, drug toxicity and unsuccessful treatment is pre-
sented in Figure 1 and described below.
Ease of administration
Adherence is only possible if caregivers are able to admin-
ister medication to the child. There was general agree-
ment among FGD participants that the nature of the child
determines the ease of administration:
The difference comes in depending on the child’s mind,
because there are some children who dislike drugs
and there are some who easily receive drugs when they
are sick. (Younger women’s FGD, 08/10/10)However, the bitter taste of medication in general was
widely reported to be the cause of the problem in diffi-
cult children. Other reasons included a total loss of ap-
petite, even for water, due to the illness and being tired
of taking so many tablets.
Participants explained that methods used to manage
difficult children varied according to their age. In general
very young children were said to be unable to discern
bad taste and were easier to administer medication to: a
mother alone could hold an infant firmly between her
legs, hold their noses or arms and force-feed the drug if
necessary. She could also breastfeed immediately after to
soothe them and prevent vomiting:
The mother gives the drug and if she just stops there,
the child will throw up, so what she does is to
immediately offer the breast to the child.
(Men’s FGD, 07/10/10)
As children grew, it was reported that one or more
other individuals may restrain them. It was frequently
mentioned that older children might hold the drug
in their mouth, later spitting it out. Participants ex-
plained that between the ages of five and 10 children
could be bribed with small gifts to take tablets, but
at this age they could also run away and hide. Older
children were described as “too wise” and not easily
bribed.
Male and older female FGD participants tended to de-
scribe physical methods, such as restraint, to ensure
younger and older children take their medication. The
younger women favoured threats for older children. Al-
though other groups described threats, the women from
HTR villages provided particularly dramatic descriptions,
such as:
“I will hit you, if you don’t take the medicine you’ll
die”. So, the child is scared because she knows that if
she doesn’t take the medicine, she’ll either die or be
whipped. (Young women’s FGD, 08/10/10)
It was apparent from the severity of the threats,
and references to physical force, that the struggle be-
tween caregivers and children may contribute to long-
term difficulty with adherence. Although infrequently
recognized, a minority of participants highlighted that
this conflict between caregivers and children leads to
the child fearing hospital treatment. This relationship
is further demonstrated by the following quote, where
hospital treatment itself was the threat:
Yes, “I will whip you, come on, swallow the drug or
else I will tell the police to arrest you or the doctor will
vaccinate you”. (Young women’s FGD, 08/10/10)
Figure 1 Representation and anti-malarial utilization. Perceptions and utilization of anti-malarials were found to be influenced by three
main factors: perceived strength; ease of administration; and knowledge and understanding of appropriate dosing and causes of unsuccessful
treatment. These factors were influenced by current or previous experience of treatment including treatment outcomes; and contributed to
under-and overdosing. NB Drug toxicity may result from overdosing. Adverse events (AEs) may occur at recommended doses. AEs only influence
individuals’ perceptions of strength and do not reflect the actual strength of the medication.
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reasoning with them, and using other positive methods
such as mixing the medication with porridge or sugar to
mask the taste.
A number of CII participants whose child received the
standard formulation of AL reported that their child either
struggled and refused to take the medication, spat it out, or
cried as a result of taking it; by comparison no such com-
ments were made by mothers of children who received dis-
persible AL. Use of physical force to ensure their child
took the medication was described by half of the CII par-
ticipants who had received standard AL, this was not re-
ported by caregivers who received dispersible AL. One
child who received dispersible AL spat out medication
taken alongside AL, but did not spit out the AL. Two CII
participants commented that their children did not com-
plain about the taste of dispersible AL, whereas they usu-
ally complain that AL is bitter. One mother remarked that:This one smells so sweet that even a difficult child
could cry for it. (Young woman CII, 20/01/11)
However, dribbling, spilling and spitting remained a
problem and were reported by 24% of FU participants in
both study arms. The benefit of dissolving rather than
crushing dispersible AL rarely featured in CIIs although
once probed a couple of participants stated dispersible
AL is easier to dissolve. 11% (11/100) of survey partici-
pants whose child received dispersible AL gave their
children dispersible tablets to chew or swallow whole.
One individual left the child to take medication them-
selves and did not observe treatment. In one FGD, the
number of tablets was described as being a problem;
participants stated the children get bored of taking so
many tablets. Figure 1 shows how challenges in adminis-
tration may lead to under-dosing, either through loss of
medication (spillage etc.) or reduced adherence.
Ewing et al. Malaria Journal  (2015) 14:13 Page 7 of 10Perceived strength
The perceived strength of anti-malarials emerged as a
major theme. Figure 1 shows how the spectrum of views
ranged from ‘too weak’ to ‘too strong’ with a small
number of individuals at both ends, but most described
both anti-malarials as good. In general, male participants
voiced more negative views:
Let’s be frank, AL is not a strong drug.
(Men’s FGD, 06/10/10)
Women, especially in HTR villages, were more positive.
Perceptions of medication strength had direct implica-
tions on adherence; individuals reported deliberately
altering the dosing schedule in accordance with the per-
ceived strength. In one FGD, participants explained that
lack of trust in the strength of anti-malarials with conse-
quent illness progression caused some individuals to give
an over-dose in order to speed up the process:
Respondent 1: You may be told to give one tablet of
AL and half a tablet of paracetamol in the morning
and in the evening, but only paracetamol at noon. We
are clearly told how to do it and yet when we come
back home, we think it is a joke and we just
administer AL in the morning, at noon and in the
evening.
Respondent 2: To do it fast…
Interviewer: …What do you mean by doing it fast?
Respondent 1: To heal fast. (Older women’s FGD,
08/10/10)
At the other end of the spectrum, one survey participant
who received AL stated she deliberately withheld tablets
because the full dose would be too strong for the child.Understanding, knowledge and clarity of instructions
Almost all survey participants reported having received in-
structions on dosing at the health facility (99%, 215/218),
and most reported having understood these instructions
(98%, 213/215). There was general understanding of the
importance of following the correct dose schedule and this
positively influenced adherence:
…we don’t stop it when we see that the child is
rejoicing but we administer the entire dosage as
instructed by the doctor. It isn’t proper to give the drug
to another child. He has to complete the dosage
prescribed to him. Each patient must have his own
dosage. (Older women’s FGD, 08/10/10)
Some individuals understood the potential impact of
poor adherence on perceptions of anti-malarials:When you don’t follow the instructions, then you tend
to think that the drug isn’t powerful enough, but when
you are told to take the drug in the morning, at noon
and in the evening, you must do so, if not, you won’t be
cured. (Men’s FGD, 06/10/10)
A number of individuals understood that unsuccessful
treatment as a result of skipping doses, taking tablets at
the incorrect time or failing to take AL with food may lead
to negative perceptions of otherwise good medications.
Figure 1 shows how poor understanding of the dosing
schedule and possible treatment outcomes was linked to
both over- and under-dosing. Despite the importance
placed on followed the correct dosing schedule, there were
knowledge gaps regarding the schedule itself. Taking the
tablets over a shorter period than recommended with
consequent over-dosing, specifically taking AL morning,
noon and evening, was frequently mentioned throughout
qualitative data collection. This was supported by the
quantitative data: 7% (7/101) of FU participants whose
child received AL reported giving tablets three times daily
rather than twice, and 3% (4/117) who received DHA-
PPQ gave tablets twice daily rather than once. Messages,
or interpretation of messages, received at the health facil-
ity contributed to inappropriate timing of doses. Partici-
pants explained that the first tablet is taken in the clinic,
and the second as soon as they get home:
We are advised to administer the drug as soon as we
return home, so when we reach home, we take the
drug and administer it to the child (Older women’s
FGD, 08/10/10)
For those living nearer to the clinic, this may be a short
time interval, and some described taking the tablets within
a couple of hours of each other, resulting in overdosing:
He takes the drug at 10 in the morning and again
at 12 O’clock and finally in the evening (Men’s FGD,
06/10/10)
Some instructions were well understood: most individ-
uals agreed that if the child vomited or spat out the medi-
cation, then another dose should be given, as instructed
by the clinic. However there was a general misunderstand-
ing that there was no need to go back to clinic to replace
this dose, and this may lead to under-dosing. Vomiting
was infrequently reported by household survey partici-
pants; 5.5% (12/218) of children had vomited following re-
cent treatment; ten caregivers did nothing, one returned
to the hospital, and one gave another tablet without re-
placing the dose. This contrast between stated under-
standing and actual behaviour suggests that other factors
determine responses to vomiting.
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standing by developing theories to explain unsuccessful
treatment and adverse events. Lack of resolution of symp-
toms following treatment and re-occurring illness were
frequent complaints. These, along with the less frequently
reported increases in symptoms or additional symptoms
following the start of anti-malarial treatment, were widely
interpreted as a lack of compatibility between the drug
and the child’s body or “blood”:
For some, it is not a suitable drug because when you
administer AL to them, the fever gets worse, for others
it is a suitable drug. (Young women’s FGD, 11/10/10)
Both FGD and CII participants described how particu-
lar medication works or does not work well consistently
in their child; the focus of these comments was the
match between the child and the drug, rather than be-
tween the drug and the cause of illness.
Such experiences caused some participants to avoid
returning to the health facility, for fear of receiving the
same drug, and led others to request clinicians prescribe
alternative medication. Participants also understood that
unsuccessful treatment could be a sign that the child’s
fever was not caused by malaria.
Discussion
Measurement of adherence is extremely challenging due
to the lack of an accurate biomarker and the influence of
study design on participants’ behaviour. This study draws
on the strengths of multiple methodologies to explore ex-
periences of using ACT. Qualitative methods, which allow
for the development of rapport with participants, were
used to explore experiences of anti-malarial use in detail,
both generally in FGDs, and during a recent course of
treatment in CII. Results were used to develop a context
specific questionnaire, which explored a wide range of as-
pects of medication use across a larger population.
Participants had generally positive perceptions of both
study drugs, in line with the observed high level of adher-
ence. Participants demonstrated a good understanding of
the importance of correct dosing; however there was some
confusion over specific details of the dosing schedule.
Non-adherence included over-dosing through taking all
doses over a shorter period than intended, taking a reduced
dose over a longer period of time and failing to complete
the entire treatment course, all of which have been previ-
ously reported [18,41,42]. Under-dosing potentially leads to
treatment failure and may contribute to the spread of anti-
malarial drug resistance. While adverse events can occur at
the recommended dosage, overdosing may lead to drug
toxicity and contribute to poor perceptions of available
anti-malarials and discourage appropriate treatment seek-
ing. Health workers involved in dispensing anti-malarialsshould be made aware of these issues and encouraged to
target these knowledge gaps when providing instructions
at the health facility.
Most FU participants reported having understood in-
structions received at the health facility, in this case pro-
vided within a study setting. Quality of instructions has
been found to significantly influence adherence [10,20,43].
A Nigerian study showed similar findings of participants
taking medication three times a day for two days or once
daily for six days, rather than twice daily for three days
and attributed this to misunderstanding of the drawings
that were used as instructions [15]. In the current study,
participants placed importance on following instructions
given at the health facility, indicating the considerable po-
tential impact of clarifying and reinforcing such messages.
Combining verbal instructions with the use of pictorial
instructions has been linked to improved adherence in
Malawi [20]: health workers should be encouraged to
make use of the pictorial instructions present on the drug
packaging. In addition, further optimization of the pack-
aging design should also be considered. Whilst qualitative
data collection suggested health education messages re-
garding the importance of giving another dose following
vomiting were getting through, the quantitative data indi-
cated this was not being put into practice.
Individuals frequently interpreted poor treatment out-
comes and adverse events as lack of compatibility between
the child and the medication. This supports findings that
individuals make decisions about the choice of treatments
based on the perceived effectiveness of the medication for
a particular set of symptoms in a specific illness episode,
rather than taking a ‘one-size-fits-all’ perspective [25].
These results emphasize the importance of ensuring both
caregivers and health facility staff have a good understand-
ing of reasons for poor treatment outcomes, possible ad-
verse events, and appropriate responses to severe adverse
events, in order to prevent community members develop-
ing theories to explain such events.
The bitter taste of medications was said to be a general
problem in administering medication to children. Chal-
lenges in administration contributed to caregivers using
threats and physical restraint during delivery of anti-
malarials. This study suggests there were some benefits
of the improved dispersible flavoured formulation in
decreasing the conflict associated with administering med-
ications, but dribbling, spilling and spitting remained a
problem in both study arms. Alternative formulations and
delivery systems need to be considered in order to im-
prove the administration of anti-malarials for all involved,
to reduce medication loss, and improve adherence.
Furthermore, the dispersible formulation is only cur-
rently available in packages suitable for the youngest age
groups, whereas participants reported most difficulty in
administering medication to older children; highlighting
Ewing et al. Malaria Journal  (2015) 14:13 Page 9 of 10the importance of considering the role of alternative for-
mulations for older children.
Despite the improved taste and solubility of dispersible
AL, our findings suggest that adherence was greater to
DHA-PPQ. This seemed largely influenced by the easier
schedule of DHA-PPQ. Both drugs were assessed within
the context of a safety and effectiveness trial, with treat-
ment provided by trained study clinicians, although previ-
ous experience with AL may have influenced adherence.
The DHA-PPQ had trial packaging with no pictorial in-
structions, so correct understanding depended on in-
structions received during dispensing and not on the
individuals’ interpretation of pictures.
Methodological issues
The level of reported adherence in this study may be
higher than that of the general population due to partici-
pation in the broader clinical effectiveness trial and asso-
ciated greater community knowledge and the dispensing
of medication by trained study clinicians, who may have
placed greater importance on adhering to instructions;
and participants’ awareness of possible home visits. It is
possible that participants exaggerated the extent to
which they were adherent due to knowledge of the
desired behaviour. Efforts were made to avoid this:
questionnaire development drew on information gained
during the qualitative phase of research, to frame ques-
tions that explored in detail the experiences of adminis-
tering medication to the child. This included probing
into any challenges experienced, in order to develop
rapport and provide a context for adherence, before
completing the adherence diary. In addition, drug pack-
aging was checked prior to questioning on adherence
and the high correlation between reported adherence
and package checks suggests the accuracy of reports.
Conclusion
Despite high overall reported adherence, caregivers ex-
perience great difficulty in administering medication to
children, the consequences of which include conflict be-
tween the child and caregiver; loss of medication; and
reduced adherence. While the sweet taste of dispersible
AL may have reduced difficulties, sub-optimal dosing
due to medication loss remained a problem and our find-
ings suggest that overall adherence was greater among
those receiving DHA-PPQ, which had a once-daily regi-
men and so required fewer doses. A lack of understanding
of the correct dosing also contributed to under- and over-
dosing. Key areas for improvement include: strengthening
health education messages around the importance of
correct dosing to parents; providing a combination of
clear pictorial and verbal instructions during dispensing;
and explaining the consequences of under and over-
dosing, alongside appropriate responses to and reportingof possible adverse events. Further optimization of anti-
malarial adherence in children requires the development
of anti-malarials with pharmacological properties that
allow user-friendly administration and simplified dosing
schedules.
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